PaxMedica
primary behavior | PaxMedica
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
20 of 24
Related slides by other companies
9 Meters Biopharma
Investor Presentation
September 2022
primary efficacy on | 9 Meters Biopharma
ATAI
Investor Presentation
October 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Theravance Biopharma
Investor Conference
November 2022
| Theravance Biopharma
ATAI
Investor Presentation
June 2020
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the phase comparative study to bridge from to a subcutaneous formulation currently in progress phase study will be completed this year randomized establish human proof of concept | ATAI
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io